

Can taking amitriptyline tablets stop long-term pain from shingles?

Submission date 17/01/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 27/01/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 01/04/2026	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Shingles is a viral infection that causes a painful rash. This study aims to find out whether taking a low dose of amitriptyline soon after getting shingles can prevent the long-term pain associated with shingles

Who can participate?

Patients aged over 50 years who have been diagnosed by their GP with shingles.

What does the study involve?

Participants take tablets nightly for 10 weeks: half will be given low-dose amitriptyline and the other half will get placebo (dummy) tablets. Pain is assessed at 90 days after rash onset.

What are the possible benefits and risks of participating?

If starting amitriptyline early on does help, it is a cheap medicine that would prevent prolonged, difficult-to-treat pain for thousands of people. However, amitriptyline commonly causes side effects such as dizziness, dry mouth and constipation. It can also cause problems when used together with some other tablets. This study is needed so doctors can be sure that any benefits outweigh any harm.

Where is the study run from?

1. University of Bristol (UK)
2. Southampton University (UK)
3. Oxford University (UK)

When is the study starting and how long is it expected to run for?

July 2021 to March 2026

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

athena-study@bristol.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mrs Christine Hawkins

Contact details

Centre for Academic Primary Care
Bristol Medical School
University of Bristol
Canyng Hall
39 Whatley Rd
Bristol
United Kingdom
BS8 2PS
+44 (0)117 9287308
athena-study@bristol.ac.uk

Type(s)

Scientific

Contact name

Prof Matthew Ridd

Contact details

Centre for Academic Primary Care
Bristol Medical School
University of Bristol
Canyng Hall
39 Whatley Rd
Bristol
United Kingdom
BS8 2PS
+44 (0)117 33 14557
m.ridd@bristol.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2021-001101-78

Integrated Research Application System (IRAS)

1003967

Central Portfolio Management System (CPMS)

50893

Study information

Scientific Title

Amitriptyline for the prevention of post-herpetic neuralgia

Acronym

ATHENA

Study objectives

Prophylactic low-dose amitriptyline will reduce post-herpetic neuralgia in patients diagnosed with herpes zoster (shingles).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 18/10/2021, South West- Central Bristol Research Ethics Committee (Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, UK; +44 (0)207 104 8029, +44 (0)207 104 8068, +44 (0)207 104 8375; centralbristol.rec@hra.nhs.uk), REC ref: 21/SW/0130

Study design

Randomized; Interventional; Design type: Treatment, Drug

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Shingles

Interventions

Amitriptyline 10 mg tablets (or matched placebo tablet), increasing in 10 mg steps over 2 weeks as tolerated, to 30 mg maximum per day, for 70 days.

Total follow-up is 12 months, with participant surveys at baseline and 30, 60, 90, 120, 180 and 360 days after rash onset.

Randomisation:

Trial participants will be allocated in a 1:1 ratio to receive amitriptyline or placebo. Randomisation will be stratified by centre and minimised on age deciles, gender at birth, pain in the last 24 hours and shingles vaccination history. The randomisation sequence will be generated by the company Sealed Envelope™ using their online randomisation system, which will allocate the participant to a treatment arm. The person undertaking the randomisation and the participant will remain masked as to which treatment group this code refers.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Amitriptyline

Primary outcome(s)

Presence/absence of postherpetic neuralgia measured using a cut-off of $\geq 3/10$ on numerical rating scale average pain in last 24 hours; Timepoint(s): 90 days after rash onset

Key secondary outcome(s)

1. The safety, tolerability and acceptability of amitriptyline assessed using patient-completed medication use, problems and hospitalisation sections of questionnaire at 30, 60 and 90 days, and by direct report by participant or clinician
2. Masking of participants assessed using the bang binding index in patient questionnaires at 30, 60 and 90 days post rash onset
3. Shorter and longer-term outcomes of pain, quality of life, mental well-being and frailty, assessed using the Zoster Brief Pain Inventory (ZBPI), 9-item patient health questionnaire (PHQ-9), 7-item general anxiety disorder questionnaire (GAD-7) and Tilburg Frailty Indicator, at 0, 90, 180 and 360 days post rash onset
4. The cost-effectiveness of low dose amitriptyline to placebo for the prevention of PHN using EQ-5D-5L and patient-completed healthcare resource use questions at 0, 90, 180 and 360 days post rash onset, and GP electronic medical records for the 12-month study period
5. Use of healthcare resources and analgesics assessed using patient-completed medication and healthcare resource use questions at 90, 180 and 360 days post rash onset, and GP electronic medical records for the 12-month study period

Completion date

31/03/2026

Eligibility**Key inclusion criteria**

1. Adults aged ≥ 50 years
2. Clinical diagnosis of herpes zoster (HZ)
3. Rash onset < 144 hours

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

50 years

Upper age limit

100 years

Sex

All

Total final enrolment

878

Key exclusion criteria

1. Inability to give informed consent
2. Third or more episode of herpes zoster
3. Known adverse reaction to amitriptyline or contraindications (monoamine oxidase inhibitors)
4. Current/recent (within previous two weeks) use of a tricyclic antidepressant
5. Prolonged QT interval or concomitant drugs that prolong the QT interval
6. Suicidal ideation
7. Heart block
8. Recent myocardial infarction (<4 weeks)
9. Immunosuppression
10. Significant bradycardia
11. Uncompensated heart failure
12. Hyperthyroidism
13. Severe liver disease
14. Pheochromocytoma
15. Urinary retention
16. If female; current or planned (in next 3 months) pregnancy or breastfeeding
17. Currently (or recently, within the previous 4 months) enrolled in another CTIMP

Date of first enrolment

30/03/2022

Date of final enrolment

30/04/2025

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University of Bristol

Senate House

Tyndall Avenue

Bristol

England

BS8 1TH

Study participating centre
University of Oxford
University Offices
Oxford
England
OX1 2JD

Study participating centre
University of Southampton
University Road
Southampton
England
SO17 1BJ

Sponsor information

Organisation
University of Bristol

ROR
<https://ror.org/0524sp257>

Funder(s)

Funder type
Government

Funder Name
NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR129720

Results and Publications

Individual participant data (IPD) sharing plan

The final anonymised trial data set will be stored as restricted data on the data.bris research data repository for at least 5 years after the end of the study. Data will be made available after the end of the study to approved bona fide researchers only after their host institution has signed a data access agreement. Details of how to request access are available at the University of Bristol's data repository website.

IPD sharing plan summary

Stored in non-publicly available repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Other publications	Qualitative interviews	31/07/2024	01/08/2024	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes